Другие заболевания миокарда

При некоторых других нечастых заболеваниях миокарда риск внезапной сердечной смерти у спортсменов также может быть повышен. К таким заболеваниям относятся: дилатационная кардиомиопатия (различной этиологии, включая наследственную), первичная негипертрофическая рестриктивная кардиомиопатия, системные инфильтративные заболевания с вторичным вовлечением сердца (например, саркоидоз) и некомпактный миокард без при наличии или отсутствии систолической дисфункции [48, 49]. Данные об относительном риске вследствие занятий спортом при вышеперечисленных заболеваниях ограничены.

Рекомендации:

До получения дополнительных сведений о влиянии перечисленных выше заболеваний на прогноз, благоразумно будет отстранить таких спортсменов от занятий любыми видами спорта, за исключением низко интенсивных (класс IA) видов спорта лишь в некоторых случаях.

Перикардит.

Рекомендации:

Спортсмены с перикардитом, вне зависимости от этиологии, должны быть отстранены от занятий любыми видами спорта во время острой стадии заболевания. Такие спортсмены могут возобновить занятия спортом вне острой стадии заболевания, включая отсутствие выпота по данным ЭхоКГ, при условии нормализации маркеров воспаления. При наличии признаков вовлечения миокарда в воспалительный процесс, тактика ведения должна быть основана на данных, изложенных в разделе Миокардит. Спортсмены с хроническим констриктивным перикардитом должны быть отстранены от занятий спортом.

Список литературы.

1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4,111 subjects in the CARDIA study: Coronary Artery Risk Development In (young) Adults. Circulation 1995;92:785–9.

2. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349: 1064 –75.

3. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687–713.

4. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308 –20.

5. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995; 92:1680 –92.

6. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003;42:1959 – 63.

7. Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med 1991;325:1753– 60.

8. Panza JA, Maron BJ. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 1989;63:1258 – 65.

9. Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002;105:2992–7.

10. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in pa-tients with hypertrophic cardiomyopathy. N Engl J Med 2000;342: 365–73.

11. Maron BJ, Mitten MJ, Quandt EF, Zipes DP. Competitive athletes with cardiovascular disease—the case of Nicholas Knapp. N Engl J Med 1998;339:1632–5.

12. Nishimura RA, McGoon MD, Shub C, Miller FA Jr., Ilstrup DM, Tajik AJ. Echocardiographically documented mitral-valve prolapse: long-term follow-up of 237 patients. N Engl J Med 1985;313:1305–9.

13. Marks AR, Choong CY, Sanfilippo AJ, Ferre M, Weyman AE. Identification of high-risk and low-risk subgroups of patients with mitral-valve prolapse. N Engl J Med 1989;320:1031– 6.

14. Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999;341:1–7.

15. Avierinos JF, Gersh BJ, Melton LJ III, et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 2002;106:1355– 61.

16. Corrado D, Basso C, Nava A, Rossi L, Thiene G. Sudden death in young people with apparently isolated mitral valve prolapse. G Ital Cardiol 1997;27:1097–105.

17. Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue: a phenotypic continuum. JAMA 1989;262:523– 8.

18. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: clinical, demo-graphic, and pathological profiles. JAMA 1996;276:199 –204.

19. Phillips M, Robinowitz M, Higgins JR, Boran KJ, Reed T, Virmani R. Sudden cardiac death in Air Force recruits: a 20-year review. JAMA 1986;256:2696 –9.

20. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1:3–14.

21. Karjalainen J, Heikkila J. Incidence of three presentations of acute myocarditis in young men in military service: a 20-year experience. Eur Heart J 1999;20:1120 –5.

22. Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL. Clinicopathologic description of myocarditis. J Am Coll Cardiol 1991;18:1617–26.

23. Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. Evidence of adeno-virus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003;42:466 –72.

24. Towbin JA. Myocarditis. In: Finberg L, Kleinman R, editors. Saun-ders Manual of Pediatric Practice. Philadelphia, PA: WB Saunders, 2002:660 –3.

25. Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis: rapid diagnosis by PCR in children. Circulation 1994;90:330 –9.

26. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352:337–9.

27. Robinson PN, Godfrey M. The molecular genetics of Marfan syn-drome and related microfibrillopathies. J Med Genet 2000;37:9 –25.

28. Pyeritz RE. Marfan syndrome and other disorders of fibrillin. In: Rimoin DL, Conner JM, Pyeritz RE, Korf B, editors. Principles and Practice of Medical Genetics. 4th edition. Edinburgh: Churchill Livingstone, 2002:3977– 4020.

29. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417–26.

30. Januzzi JL, Isselbacher EM, Fattori R, et al. Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). J Am Coll Cardiol 2004;43:665–9.

31. Marsalese DL, Moodie DS, Vacante M, et al. Marfan’s syndrome: natural history and long-term follow-up of cardiovascular involvement. J Am Coll Cardiol 1989;14:422– 8.

32. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med 1994;330:1335– 41.

33. Yetman AT, Bornemeier RA, McCrindle BW. Long-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death? J Am Coll Cardiol 2003;41:329 –32.

34. Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan’s syndrome. N Engl J Med 1999;340:1307–13.

35. de Virgilio C, Nelson RJ, Milliken J, et al. Ascending aortic dissection in weight lifters with cystic medial degeneration. Ann Thorac Surg 1990;49:638 – 42.

36. Elefteriades JA, Hatzaras I, Tranquilli MA, et al. Weight lifting and rupture of silent aortic aneurysms. JAMA 2003;290:2803.

37. Ferencik M, Pape LA. Changes in size of ascending aorta and aortic valve function with time in patients with congenitally bicuspid aortic valves. Am J Cardiol 2003;92:43– 6.

38. Hahn RT, Roman MJ, Mogtader AH, Devereux RB. Association of aortic dilation with regurgitant, stenotic and functionally normal bicuspid aortic valves. J Am Coll Cardiol 1992;19:283– 8.

39. Roberts CS, Roberts WC. Dissection of the aorta associated with congenital malformation of the aortic valve. J Am Coll Cardiol 1991;17:712– 6.

40. Nistri S, Sorbo MD, Marin M, Palisi M, Scognamiglio R, Thiene G. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart 1999;82:19 –22.

41. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004;44:138 –43.

42. Lewin MB, McBride KL, Pignatelli R, et al. Echocardiographic evaluation of asymptomatic parental and sibling cardiovascular anom-alies associated with congenital left ventricular outflow tract lesions. Pediatrics 2004;114:691–96.

43. Roman MJ, Devereux RB, Kramer-Fox R, O’Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989;64:507–12.

44. Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopa-thy and/or dysplasia. Circulation 2003;108:3000 –5.

45. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol 1997;30:1512–20.

46. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circula-tion 2003;108:3084 –91.

47. Bowles NE, Ni J, Marcus F, Towbin JA. The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2002;39:892–5.

48. Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol 2000;36:493–500.

49. Pignatelli RH, McMahon CJ, Dreyer WJ, et al. Clinical characteriza-tion of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation 2003;108:2672– 8.

50. Woo A., Rakowski H., Liew J. C. et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart 2003;89:1179-1185.

51. Fananapazir L. Advances in molecular genetics and management of hypertrophic cardiomyopathy [clinical conference]. JAMA 1999;281:1746-1752.

52. Marian A. J. Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers. Clin. Cardiol 1995;18:189-198.

53. Д.М. Селезнёв, С.А. Габрусенко, Е.В. Парфёнова, В.Г. Наумов,Д.В. Стамбольский, В.А. Ткачук. Роль мутаций в гене тяжелой цепи сердечного b-миозина в российской популяции больных гипертрофической кардиомиопатией.Кардиология 2005;4: 15-20.

54. Габрусенко С.А. Гипертрофическая кардиомиопатия: клинико-инструментальная характеристика, варианты клинического течения, прогноз и особенности медикаментозного лечения. Дисс. докт. мед. наук, M., 2009, 309 стр.

55. Charron P., Dubourg O., Desnos M. et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 1998;97: 2230-2236.

56. Watkins H., McKenna W. J., Thierfelder L. et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058-1064.

57. Jongbloed R. J., Marcelis C. L., Doevendans P.A. et al. Variable clinical manifestation of a novel missense mutation in the alpha-tropomyosin (TPM1) gene in familial hypertrophic cardiomyopathy. JACC 2003;41:981-986.